Unfortunately, several recent clinical reports suggest that anti-VEGF treatment may in fact promote a pro-migratory cellular tumor phenotype in patients with recurrent glioblastoma (for example [24, 102]). The gene discussed is VEGFA; the disease is neoplasm.